StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Thursday morning. The firm issued a hold rating on the stock.

Other research analysts also recently issued research reports about the stock. JMP Securities upped their target price on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a market outperform rating in a research note on Wednesday, July 31st. HC Wainwright reaffirmed a buy rating and issued a $5.00 price objective on shares of DBV Technologies in a research report on Thursday, August 1st.

DBV Technologies Stock Up 3.3 %

DBV Technologies stock opened at $0.73 on Thursday. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $2.97. The company has a market capitalization of $70.76 million, a P/E ratio of -0.87 and a beta of 0.68. The stock’s 50 day moving average is $0.88 and its 200 day moving average is $1.11.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Tuesday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). The company had revenue of $1.16 million during the quarter, compared to analysts’ expectations of $1.42 million. DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. During the same period in the prior year, the company posted ($0.26) earnings per share. As a group, equities analysts expect that DBV Technologies will post -1.43 EPS for the current year.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. boosted its stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the period. DBV Technologies comprises 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the Securities & Exchange Commission. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.